Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Belgium
Study Type
Interventional
Intervention
Functional Respiratory Imaging
Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Seretide Evohaler
Placebo of Test product
Placebo of Reference product
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Salmeterol xinafoate and Fluticasone propionate, Seretide Evohaler, Functional Respiratory Imaging, Computational Fluid Dynamic
Eligibility Criteria
Inclusion Criteria:
- Male or female patient ≥ 18 years old
- Written informed consent obtained
- Patient with a documented diagnosis of asthma according to the GINA guidelines
- Patient with a co-operative attitude and ability to be trained to correctly use the pMDI
- Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study
- Patient must be stable and treated in accordance with the GINA guidelines
- Patient must be a non-smoker or ex-smoker who have stopped smoking at least 1 year prior to visit 1 and has a smoking history of < 10 pack years
- Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions
Exclusion Criteria:
- Pregnant or lactating female
- Unstable patient who developed an exacerbation during the last 8 weeks
- Patient with upper or lower airways infection
- Patient unable to carry out pulmonary function testing
- Patient with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
- Patient with cancer or any other chronic disease with poor prognosis and /or affecting patient status
- Patient with allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
- Patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
- Patient who received oral corticosteroids within the last 4 weeks prior to visit 1
- Patient who received any investigational new drug within the last 4 weeks prior to visit 1 or twice the duration of the biological effect of any drug (whichever is longer)
- Patient with a history of alcohol or substance abuse that in the opinion of the investigator may be of clinical significance
- Patient who has undergone major surgery in the last 12 weeks before the visit 1 or has planned to undergo a major surgery before the end of the trial
- Patient with diagnosis of chronic obstructive pulmonary disease (COPD)
Sites / Locations
- Antwerp University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Seretide Evohaler
Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Arm Description
Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK) Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg
Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India) Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg
Outcomes
Primary Outcome Measures
Total airway volume
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
The number of deposited particles per pre-defined airway section
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Total airway resistance
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Total airway volume
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
The number of deposited particles per pre-defined airway section
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Total airway resistance
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Secondary Outcome Measures
Lung function tests (spirometry, body plethysmography)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Exercise capacity (6 minutes walking test)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Dyspnea (BORG CR 10 scale and VAS dyspnea)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Incidence of adverse events
The safety of the 2 products under investigation will be evaluated through monitoring of adverse events (AEs) throughout the study.
Lung function tests (spirometry, body plethysmography)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Exercise capacity (6 minutes walking test)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Dyspnea (BORG CR 10 scale and VAS dyspnea)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01795664
Brief Title
Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
Official Title
A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Seretide® Evohaler (Supplied by Allen & Hanburys, UK) and a Generic Salmeterol/Fluticasone HFA pMDI (Manufactured by Cipla Ltd, India) on Functional Respiratory Imaging Parameters in Asthmatic Patients.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
FLUIDDA nv
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will be conducted as a randomized, double blind, double dummy two period crossover study in stable asthma patients. A total of 16 stable asthma patients treated in accordance with the Global Initiative for Asthma (GINA) guidelines, will be included.
Objectives:
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea). Furthermore the safety of the 2 products under investigation will be evaluated through monitoring of adverse events (AEs) throughout the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Salmeterol xinafoate and Fluticasone propionate, Seretide Evohaler, Functional Respiratory Imaging, Computational Fluid Dynamic
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Seretide Evohaler
Arm Type
Active Comparator
Arm Description
Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)
Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg
Arm Title
Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Arm Type
Experimental
Arm Description
Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)
Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg
Intervention Type
Radiation
Intervention Name(s)
Functional Respiratory Imaging
Intervention Description
CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
Intervention Type
Drug
Intervention Name(s)
Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Other Intervention Name(s)
Test product
Intervention Description
Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)
Intervention Type
Drug
Intervention Name(s)
Seretide Evohaler
Other Intervention Name(s)
Reference product, Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI
Intervention Description
Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)
Intervention Type
Drug
Intervention Name(s)
Placebo of Test product
Other Intervention Name(s)
Placebo inhaler containing HFA propellant resembling the test active inhaler
Intervention Description
Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
Intervention Type
Drug
Intervention Name(s)
Placebo of Reference product
Other Intervention Name(s)
Placebo inhaler containing HFA propellant resembling the reference active inhaler
Intervention Description
Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
Primary Outcome Measure Information:
Title
Total airway volume
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
The number of deposited particles per pre-defined airway section
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
Total airway resistance
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
Total airway volume
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 3 (= 3-7 days after visit 2)
Title
The number of deposited particles per pre-defined airway section
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 3 (= 3-7 days after visit 2)
Title
Total airway resistance
Description
The primary objective of this study is to evaluate the effect of both the study drugs under investigation on Functional Respiratory Imaging (FRI) parameters and to evaluate the particle deposition in the lungs using Computational Fluid Dynamic (CFD)
Time Frame
At visit 3 (= 3-7 days after visit 2)
Secondary Outcome Measure Information:
Title
Lung function tests (spirometry, body plethysmography)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
Exercise capacity (6 minutes walking test)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
Dyspnea (BORG CR 10 scale and VAS dyspnea)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 2 (= 7-11 days after visit 1)
Title
Incidence of adverse events
Description
The safety of the 2 products under investigation will be evaluated through monitoring of adverse events (AEs) throughout the study.
Time Frame
From visit 1 until visit 4 = timeperiod of 3 à 4 weeks
Title
Lung function tests (spirometry, body plethysmography)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 3 (= 3-7 days after visit 2)
Title
Exercise capacity (6 minutes walking test)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 3 (= 3-7 days after visit 2)
Title
Dyspnea (BORG CR 10 scale and VAS dyspnea)
Description
The secondary objectives are to assess the effect of both the study drugs on lung function (spirometry and body plethysmography), on exercise capacity (6 Minutes Walking Test = 6MWT) and on dyspnea (Borg Category (C) Ratio (R) 10 Scale and Visual Analog Scale (VAS) dyspnea).
Time Frame
At visit 3 (= 3-7 days after visit 2)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patient ≥ 18 years old
Written informed consent obtained
Patient with a documented diagnosis of asthma according to the GINA guidelines
Patient with a co-operative attitude and ability to be trained to correctly use the pMDI
Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study
Patient must be stable and treated in accordance with the GINA guidelines
Patient must be a non-smoker or ex-smoker who have stopped smoking at least 1 year prior to visit 1 and has a smoking history of < 10 pack years
Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions
Exclusion Criteria:
Pregnant or lactating female
Unstable patient who developed an exacerbation during the last 8 weeks
Patient with upper or lower airways infection
Patient unable to carry out pulmonary function testing
Patient with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
Patient with cancer or any other chronic disease with poor prognosis and /or affecting patient status
Patient with allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
Patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
Patient who received oral corticosteroids within the last 4 weeks prior to visit 1
Patient who received any investigational new drug within the last 4 weeks prior to visit 1 or twice the duration of the biological effect of any drug (whichever is longer)
Patient with a history of alcohol or substance abuse that in the opinion of the investigator may be of clinical significance
Patient who has undergone major surgery in the last 12 weeks before the visit 1 or has planned to undergo a major surgery before the end of the trial
Patient with diagnosis of chronic obstructive pulmonary disease (COPD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wilfried De Backer, MD, PhD
Organizational Affiliation
University Hospital, Antwerp
Official's Role
Principal Investigator
Facility Information:
Facility Name
Antwerp University Hospital
City
Edegem
State/Province
Antwerp
ZIP/Postal Code
2650
Country
Belgium
12. IPD Sharing Statement
Citations:
PubMed Identifier
27227384
Citation
De Backer J, Van Holsbeke C, Vos W, Vinchurkar S, Dorinsky P, Rebello J, Mangale M, Hajian B, De Backer W. Assessment of lung deposition and analysis of the effect of fluticasone/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in stable persistent asthma patients using functional respiratory imaging. Expert Rev Respir Med. 2016 Aug;10(8):927-33. doi: 10.1080/17476348.2016.1192464. Epub 2016 Jun 1.
Results Reference
derived
Learn more about this trial
Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
We'll reach out to this number within 24 hrs